Issues in regulatory guidelines for data monitoring committees

David DeMets, Robert Califf, Dennis Dixon, Susan Ellenberg, Thomas Fleming, Peter Held, Desmond Julian, Richard Kaplan, Robert Levine, James Neaton, Milton Packer, Stuart Pocock, Frank Rockhold, Belinda Seto, Jay Siegel, Steve Snapinn, David Stump, Robert Temple, Richard Whitley

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


As clinical trials have emerged as the major research method for evaluating new interventions, the process for monitoring intervention safety and benefit has also evolved. The Data Monitoring Committee (DMC) has become the standard approach to implement this responsibility for many Phase III trials. Recent draft guidelines on the operation of DMCs by the Food and Drug Administration (FDA) have raised issues that need further clarification or discussion, especially for industry sponsored trials. These include, the time when DMCs are needed, the role of the independent statistician to support the DMC, and sponsor participation at DMC meetings. This paper provides an overview of these issues, based on the discussions at the January, 2003 workshop sponsored by Duke Clinical Research Institute.

Original languageEnglish (US)
Pages (from-to)162-169
Number of pages8
JournalClinical Trials
Issue number2
StatePublished - Apr 2004

ASJC Scopus subject areas

  • Pharmacology


Dive into the research topics of 'Issues in regulatory guidelines for data monitoring committees'. Together they form a unique fingerprint.

Cite this